• PDF / 169,655 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 52 Downloads / 141 Views

DOWNLOAD

REPORT

---

1 S

Dermatitis and hypothyroidism: case report A 62-year-old woman developed mild dermatitis and hypothyroidism during treatment with denosumab and pembrolizumab for stage IVB metastatic uterine leiomyosarcoma [duration of treatments to reaction onsets and outcomes not stated]. The woman, who had a history of stage IVB uterine leiomyosarcoma with histologically proved pulmonary metastasis and spinal metastasis was initially treated with gemcitabine and docetaxel along with peg-filgrastim. Additionally, she started receiving denosumab 120mg injection every 28 days for bone metastasis. A mixed response of the lung and bone metastases was observed. Based on her symptoms and the extent of the pulmonary disease, a chemotherapy regimen involving doxorubicin, mesna, ifosfamide and dacarbazine was started along with continuation of denosumab. The CT scans revealed an interval decrease in pulmonary nodules and left pleural effusions, but no change in her bony lesion after 3 cycles. Therefore, further treatment was started with IV pembrolizumab 200mg every 21 days from June 2018. Imaging studies after 10 cycles revealed stable disease. However, she developed mild dermatitis. The woman’s dermatitis resolved with unspecified topical steroids. Thereafter, she also developed hypothyroidism (grade I) before cycle 11, which was treated with levothyroxine. After 2 weeks, her treatment was resumed and she was noted to have stable disease. Cotangco K, et al. Stabilization of metastatic uterine leiomyosarcoma using pembrolizumab. Journal of the National Comprehensive Cancer Network 18: 1012-1014, No. 8, 803519218 Aug 2020. Available from: URL: http://doi.org/10.6004/jnccn.2020.7562

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833